Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors

Merck (MRK) has garnered a "Strong Buy" rating driven by strategic initiatives aimed at securing long-term growth and mitigating patent expiry risks. Key among these is the FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor, which extends Keytruda's patent life beyond the anticipated 2028 cliff and offers enhanced patient convenience. Additionally, the acquisition of Verona Pharma, adding Ohtuvayre for COPD, strategically expands Merck's cardiopulmonary portfolio, reinforcing its future growth prospects despite flat overall Q2 2025 sales, as Keytruda's oncology performance remains robust.

Analysis

Merck (MRK) is executing a clear, two-pronged strategy to secure long-term growth and mitigate the upcoming 2028 patent cliff for its blockbuster drug, Keytruda. The recent FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor, is a pivotal development in its life-cycle management strategy. This new formulation not only extends the patent protection of the Keytruda franchise but also offers a competitive advantage through more rapid and flexible dosing, potentially expanding its use into broader treatment settings. Concurrently, MRK is actively diversifying its revenue streams through strategic M&A, as evidenced by the acquisition of Verona Pharma. This transaction adds Ohtuvayre for COPD to its pipeline, significantly strengthening its cardiopulmonary portfolio. While the article notes that overall sales for Q2 2025 are projected to be flat, the sustained strong performance of Keytruda in the oncology market provides a stable financial base to support these long-term growth initiatives, reinforcing a bullish outlook.

Key Decisions for Investors

• Investors should consider the recent FDA approval of QLEX and the Verona Pharma acquisition as significant de-risking events that directly address the 2028 Keytruda patent cliff and add new long-term growth drivers.
• It is prudent to monitor the commercial uptake and market share gains of the subcutaneous QLEX formulation, as its success is a key catalyst for offsetting the eventual revenue decline from the intravenous version of Keytruda.
• Consider looking beyond near-term financial metrics, such as the flat Q2 2025 sales forecast, and focus on the execution of the company's long-term strategy in oncology life-cycle management and cardiopulmonary expansion.